20 articles
Single-cell analysis reveals how the flavonoid fisetin may reduce neuroinflammation in Alzheimer's disease by targeting specific astrocyte subgroups.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
Study shows 2'-fucosyllactose improves cognitive function in mice by modulating gut microbiota and brain serotonin levels.
A 3-month fish hydrolysate supplement significantly improved episodic memory in healthy seniors showing accelerated cognitive decline, with reduced inflammation markers.
A naturally occurring fatty acid amide activates immune cells in the retina, protecting neurons and blood vessels from degenerative damage.
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
A boy with PLCB1-related epileptic encephalopathy showed improved seizure control and stabilized brain atrophy after high-dose enteral myo-inositol supplementation.
Breakthrough antisense therapy demonstrates sustained benefits for rare genetic form of ALS in extended clinical trial.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
Nicotinamide riboside prevents moyamoya-like brain vessel blockages by fixing cellular energy production in smooth muscle cells.
Researchers discover a phospholipid derivative that protects brain cells by calming overactive immune cells in dementia-prone mice.
The FINI instrument measures six key life domains in narcolepsy patients, offering clinicians a richer picture than sleepiness scales alone.
A Cochrane review of two RCTs finds very low-certainty evidence that IGF-1 neither prevents nor worsens retinopathy of prematurity in extremely preterm infants.
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
New research identifies FTL1 protein as key driver of brain aging. Reducing it restored memory and neural connections in mice.
32-person study explores how intermittent fasting affects blood vessel function and brain performance through protective pathways.
New research maps a stress-signaling cascade linking p53 activation to brain inflammation and depression, with curcumin interrupting it.
New drug FP802 disrupts toxic brain signaling, preventing memory loss and brain damage in Alzheimer's mouse models.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
